Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16

Journal of Virology

Volumn 87, Issue 21, 2013, Pages 11426-11437

  Richards, Kathleen F ^a   Bienkowska Haba, Malgorzata ^a,b   Dasgupta, Jhimli ^c   Chen, Xiaojiang S ^c   Sapp, Martin ^a,b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN L2; HEPARAN SULFATE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL COMPARTMENTALIZATION; CELL SURFACE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENDOSOME; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INDUCTION; VIRUS UNCOATING;

BINDING SITES; CAPSID PROTEINS; CELL LINE; DNA MUTATIONAL ANALYSIS; HEPARITIN SULFATE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MUTANT PROTEINS; ONCOGENE PROTEINS, VIRAL; VIRUS INTERNALIZATION;

EID: 84886879612     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01721-13     Document Type: Article

References (62)

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121:621-632.
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87:796-802.
3. Zur Hausen H. 2009. Papillomaviruses in the causation of human cancers- a brief historical account. Virology 384:260-265.
4. Doorbar J. 2005. The papillomavirus life cycle. J. Clin. Virol. 32(Suppl. 1):S7-S15.
5. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757.
6. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT. 2005. Maturation of papillomavirus capsids. J. Virol. 79:2839-2846.
7. Leder C, Kleinschmidt JA, Wiethe C, Muller M. 2001. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 75:9201-9209.
8. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. 1991. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys. J. 60:1445-1456.
9. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. 2000. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 5:557-567.
10. Modis Y, Trus BL, Harrison SC. 2002. Atomic model of the papillomavirus capsid. EMBO J. 21:4754-4762.
11. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL. 2008. Arrangement of L2 within the papillomavirus capsid. J. Virol. 82:5190-5197.
12. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565-1570.
13. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274:5810-5822.
14. Li M, Beard P, Estes PA, Lyon MK, Garcea RL. 1998. Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J. Virol. 72: 2160-2167.
15. Sapp M, Fligge C, Petzak I, Harris JR, Streeck RE. 1998. Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J. Virol. 72:6186-6189.
16. Roden RB, Day PM, Bronzo BK, Yutzy WH, IV, Yang Y, Lowy DR, Schiller JT. 2001. Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J. Virol. 75:10493-10497.
17. Zhao KN, Sun XY, Frazer IH, Zhou J. 1998. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243:482-491.
18. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM. 2009. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 83:2067-2074.
19. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. 2003. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77:13125-13135.
20. Selinka HC, Florin L, Patel HD, Freitag K, Schmidtke M, Makarov VA, Sapp M. 2007. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J. Virol. 81:10970-10980.
21. Lindahl U, Kusche-Gullberg M, Kjellen L. 1998. Regulated diversity of heparan sulfate. J. Biol. Chem. 273:24979-24982.
22. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J. Clin. Invest. 108:169-173.
23. Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, Sapp M. 2007. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J. Biol. Chem. 282:27913-27922.
24. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT. 2008. Mechanisms of human papillomavirus type 16 neutralization by L2 crossneutralizing and L1 type-specific antibodies. J. Virol. 82:4638-4646.
25. Day PM, Lowy DR, Schiller JT. 2008. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J. Virol. 82:12565-12568.
26. Scheffer KD, Gawlitza A, Spoden GA, Zhang XA, Lambert C, Berditchevski F, Florin L. 2013. Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J. Virol. 87:3435-3446.
27. Abban CY, Meneses PI. 2010. Usage of heparan sulfate, integrins, and FAK in HPV16 infection. Virology 403:1-16.
28. 6 Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem. Biophys. Res. Commun. 283:668-673.
29. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. 1997. Identification of the α6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71:2449-2456.
30. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, Lambert C, Florin L. 2008. Clathrin- and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PLoS One 3:e3313. doi:10.1371/journal.pone.0003313.
31. Surviladze Z, Dziduszko A, Ozbun MA. 2012. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog. 8:e1002519. doi:10.1371/journal.ppat.1002519.
32. Surviladze Z, Sterk RT, DeHaro SA, Ozbun MA. 2013. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy. J. Virol. 87:2508-2517.
33. Woodham AW, Da Silva DM, Skeate JG, RaffAB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM. 2012. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 7:e43519. doi:10.1371/journal.pone.0043519.
34. Dziduszko A, Ozbun MA. 2013. Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes. J. Virol. 87:7502-7515.
35. Cerqueira C, Liu Y, Kuhling L, Chai W, Hafezi W, van Kuppevelt TH, Kuhn JE, Feizi T, Schelhaas M. 18 April 2013. Heparin increases the infectivity of human papillomavirus type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell. Microbiol. [Epub ahead of print.] doi:10.1111/cmi.12150.
36. Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT. 2007. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81:8784-8792.
37. Richards RM, Lowy DR, Schiller JT, Day PM. 2006. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. U. S. A. 103:1522-1527.
38. Bienkowska-Haba M, Patel HD, Sapp M. 2009. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog. 5:e1000524. doi:10.1371/journal.ppat.1000524.
39. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M. 2003. Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77:12961-12967.
40. Roth SD, Sapp M, Streeck RE, Selinka HC. 2006. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol. J. 3:83. doi:10.1186/1743-422X-3-83.
41. Dasgupta J, Bienkowska-Haba M, Ortega ME, Patel HD, Bodevin S, Spillmann D, Bishop B, Sapp M, Chen XS. 2011. Structural basis of oligosaccharide receptor recognition by human papillomavirus. J. Biol. Chem. 286:2617-2624.
42. Rommel O, Dillner J, Fligge C, Bergsdorf C, Wang X, Selinka HC, Sapp M. 2005. Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J. Med. Virol. 75:114-121.
43. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. 1996. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184.
44. Sapp M, Kraus U, Volpers C, Snijders PJ, Walboomers JM, Streeck RE. 1994. Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J. Gen. Virol. 75(Part 12):3375-3383.
45. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB. 2007. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 81: 13927-13931.
46. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, Day PM, Schiller JT, Helenius A. 2012. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog. 8:e1002657. doi:10.1371/journal.ppat.1002657.
47. Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M. 2012. Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. J. Virol. 86:9875-9887.
48. Campos SK, Chapman JA, Deymier MJ, Bronnimann MP, Ozbun MA. 2012. Opposing effects of bacitracin on human papillomavirus type 16 infection: enhancement of binding and entry and inhibition of endosomal penetration. J. Virol. 86:4169-4181.
49. Day PM, Lowy DR, Schiller JT. 2003. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307:1-11.
50. Bousarghin L, Touze A, Sizaret PY, Coursaget P. 2003. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J. Virol. 77:3846-3850.
51. Smith JL, Campos SK, Wandinger-Ness A, Ozbun MA. 2008. Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J. Virol. 82:9505-9512.
52. Huang HS, Buck CB, Lambert PF. 2010. Inhibition of gamma secretase blocks HPV infection. Virology 407:391-396.
53. Karanam B, Peng S, Li T, Buck C, Day PM, Roden RB. 2010. Papillomavirus infection requires gamma secretase. J. Virol. 84:10661-10670.
54. Bergsdorf C, Beyer C, Umansky V, Werr M, Sapp M. 2003. Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles. FEBS Lett. 536: 120-124.
55. Schmidtke M, Karger A, Meerbach A, Egerer R, Stelzner A, Makarov V. 2003. Binding of a N, N=-bisheteryl derivative of dispirotripiperazine to heparan sulfate residues on the cell surface specifically prevents infection of viruses from different families. Virology 311:134-143.
56. Schmidtke M, Riabova O, Dahse HM, Stelzner A, Makarov V. 2002. Synthesis, cytotoxicity and antiviral activity of N, N=-bis-5-nitropyrimidyl derivatives of dispirotripiperazine. Antiviral Res. 55:117-127.
57. Schowalter RM, Pastrana DV, Buck CB. 2011. Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry. PLoS Pathog. 7:e1002161. doi:10.1371/journal.ppat.1002161.
58. Belnap DM, McDermott BM, Jr, Filman DJ, Cheng N, Trus BL, Zuccola HJ, Racaniello VR, Hogle JM, Steven AC. 2000. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 97:73-78.
59. Hogle JM. 2002. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu. Rev. Microbiol. 56:677-702.
60. Xing L, Casasnovas JM, Cheng RH. 2003. Structural analysis of human rhinovirus complexed with ICAM-1 reveals the dynamics of receptormediated virus uncoating. J. Virol. 77:6101-6107.
61. Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA. 2003. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J. Virol. 77:11625-11632.
62. Wolf M, Garcea RL, GrigorieffN, Harrison SC. 2010. Subunit interactions in bovine papillomavirus. Proc. Natl. Acad. Sci. U. S. A. 107:6298-6303.